These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12942128)

  • 1. Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue.
    Chini B; Chinol M; Cassoni P; Papi S; Reversi A; Areces L; Marrocco T; Paganelli G; Manning M; Bussolati G
    Br J Cancer; 2003 Sep; 89(5):930-6. PubMed ID: 12942128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 111In-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-lys(8)-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumors.
    Bussolati G; Chinol M; Chini B; Nacca A; Cassoni P; Paganelli G
    Cancer Res; 2001 Jun; 61(11):4393-7. PubMed ID: 11389066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
    de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular cloning and functional characterization of the oxytocin receptor from a rat pancreatic cell line (RINm5F).
    Jeng YJ; Lolait SJ; Strakova Z; Chen C; Copland JA; Mellman D; Hellmich MR; Soloff MS
    Neuropeptides; 1996 Dec; 30(6):557-65. PubMed ID: 9004255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Novel
    Poret B; Desrues L; Bonin MA; Pédard M; Dubois M; Leduc R; Modzelewski R; Decazes P; Morin F; Vera P; Castel H; Bohn P; Gandolfo P
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32204509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological activities of a photoaffinity probe for vasotocin and oxytocin receptors.
    Fahrenholz F; Eggena P; Kojro E; Gazis D; Schwartz IL
    Int J Pept Protein Res; 1987 Nov; 30(5):577-82. PubMed ID: 2830197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new tritiated oxytocin receptor radioligand--synthesis and application for localization of central oxytocin receptors.
    Klein U; Jurzak M; Gerstberger R; Fahrenholz F
    Peptides; 1995; 16(5):851-7. PubMed ID: 7479326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
    Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
    Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.
    Tolmachev V; Rosik D; Wållberg H; Sjöberg A; Sandström M; Hansson M; Wennborg A; Orlova A
    Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):613-22. PubMed ID: 19838701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting.
    Heppeler A; André JP; Buschmann I; Wang X; Reubi JC; Hennig M; Kaden TA; Maecke HR
    Chemistry; 2008; 14(10):3026-34. PubMed ID: 18246556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of neurohypophysial hormone receptor domains involved in ligand binding and G protein coupling.
    Postina R; Kojro E; Fahrenholz F
    Adv Exp Med Biol; 1998; 449():371-85. PubMed ID: 10026828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification, localization and functional in vitro and in vivo activity of oxytocin receptor in the rat penis.
    Zhang XH; Filippi S; Vignozzi L; Morelli A; Mancina R; Luconi M; Donati S; Marini M; Vannelli GB; Forti G; Maggi M
    J Endocrinol; 2005 Mar; 184(3):567-76. PubMed ID: 15749815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of DOTA position on melanoma targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide.
    Guo H; Yang J; Gallazzi F; Prossnitz ER; Sklar LA; Miao Y
    Bioconjug Chem; 2009 Nov; 20(11):2162-8. PubMed ID: 19817405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of Oxytocin Analogs.
    Wiśniewski K
    Methods Mol Biol; 2019; 2001():235-271. PubMed ID: 31134574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxytocin antagonist [1-D(CH2)5,Tyr(ME)2,Thr4,Tyr-NH2(9)]ornithine vasotocin inhibits oxytocin-induced prostaglandin F2alpha release in late-pregnant cows.
    Fuchs AR; Fields MJ; Chang SM; Thatcher WW; Willard CC; Randel RD
    Biol Reprod; 1997 Aug; 57(2):436-41. PubMed ID: 9241061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of binding affinity of oxytocin antagonists to human and rat uterine oxytocin receptors and their correlation to the rat uterine oxytocic bioassay.
    Pak SC; Bertoncini D; Meyer W; Scaunas D; Flouret G; Wilson L
    Biol Reprod; 1994 Dec; 51(6):1140-4. PubMed ID: 7888492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
    Gimpl G; Postina R; Fahrenholz F; Reinheimer T
    Eur J Pharmacol; 2005 Mar; 510(1-2):9-16. PubMed ID: 15740719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.
    Chappell LL; Ma D; Milenic DE; Garmestani K; Venditto V; Beitzel MP; Brechbiel MW
    Nucl Med Biol; 2003 Aug; 30(6):581-95. PubMed ID: 12900284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors.
    Busnelli M; Bulgheroni E; Manning M; Kleinau G; Chini B
    J Pharmacol Exp Ther; 2013 Aug; 346(2):318-27. PubMed ID: 23723434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.